Description

Dobutamin (dobutamine) Admeda solution for infusions 250 mg. 50 ml. №1

Ingredients:

Each 50 ml vial contains 250 mg of dobutamine hydrochloride as the active ingredient.

Dosage:

The dosage of Dobutamin should be individualized based on the patient’s condition and response to treatment. It is administered intravenously by a healthcare professional.

Indications:

Dobutamin is indicated for the short-term treatment of adults with cardiac decompensation due to depressed contractility, either in the presence of normal or raised filling pressures.

Contraindications:

Do not use Dobutamin in patients with idiopathic hypertrophic subaortic stenosis, known hypersensitivity to dobutamine, or uncorrected tachyarrhythmias.

Directions:

Dobutamin should be administered by healthcare professionals experienced in the management of acute cardiac disorders. The infusion rate should be adjusted to achieve the desired hemodynamic effect.

Scientific Evidence:

Dobutamine is a synthetic catecholamine with predominantly beta-1 adrenergic agonist activity, resulting in increased myocardial contractility and stroke volume. It acts by stimulating beta-1 adrenergic receptors in the heart, leading to increased cardiac output. Clinical studies have demonstrated the effectiveness of dobutamine in improving cardiac function in patients with acute heart failure.

Additional Information:

Dobutamine is commonly used in the critical care setting to support cardiac function in patients with acute decompensated heart failure or during cardiac stress testing. It is considered a first-line agent for inotropic support in patients with reduced cardiac contractility. Dobutamine’s rapid onset of action and short half-life make it a valuable tool in managing acute cardiac conditions.